COVID-19 Vaccines May Trigger Takotsubo Cardiomyopathy: Research

By Dr Frank Yap, M.D. -
Various vaccines have been rapidly developed and administered in response to the COVID-19 pandemic. However, accompanying the widespread vaccination efforts, there has been a notable increase in the occurrence of side effects and adverse events related to COVID-19 vaccines. Research has unveiled a potential association between COVID-19 vaccines and Takotsubo cardiomyopathy, with two fatalities among 16 patients.

Takotsubo cardiomyopathy

The clinical presentation of Takotsubo cardiomyopathy (TCM) resembles that of acute myocardial infarction, with common symptoms including acute chest pain and breathlessness. Its hallmark is impaired left ventricular function, typically occurring after intense emotional or physical stressors such as the death of a loved one, traumatic events, or severe illness. This condition, first identified by Japanese physician Dr. Hikaru Sato in 1990, is named “Takotsubo” due to the balloon-like bulging of the left ventricle, resembling the octopus-catching pot used in Japan.

Outside of Japan, Takotsubo cardiomyopathy is also referred to as stress cardiomyopathy, apical ballooning syndrome, or broken heart syndrome.

A Case Study

In August, a case report was published in the journal Cureus detailing the experience of a 59-year-old woman who developed Takotsubo cardiomyopathy after receiving a booster dose of the COVID-19 vaccine. The patient experienced persistent dyspnea for six hours, prompting her visit to the emergency department. According to the patient’s account, she had been experiencing intermittent chest pain for the past two days, described as a stabbing sensation that progressively intensified with each episode but did not radiate to other areas. Exertion worsened the pain, and there was no relief method. The patient had received the Moderna vaccine booster dose three days prior.

The patient did not have a fever and remained conscious, with a blood oxygen saturation of 89 percent and blood pressure at 150/90 mmHg. Crackling and rattling sounds known as crepitations were detected in her lungs. A COVID-19 polymerase chain reaction test yielded a negative result. The emergency electrocardiogram showed ST-segment elevation, a chest X-ray revealed pulmonary edema and an ultrasound indicated reduced left ventricular systolic function, with an estimated ejection fraction of 30 percent. Additionally, there was moderate hypokinesia (abnormally diminished motor activity) in the apex and anterior wall of the heart.

The patient continued to experience tachycardia and blood pressure fluctuations, leading to hemodynamic instability due to fluid overload and ultimately resulting in cardiac shock. The medical team administered intravenous injections of norepinephrine and dobutamine for treatment. As no other etiologies were identified, she was diagnosed with Takotsubo cardiomyopathy.

The patient showed improvement and was discharged on the sixth day but continued to experience persistent tachycardia, requiring treatment with metoprolol, a medication for the treatment of high blood pressure.

Before receiving the vaccine, the patient had a history of hyperlipidemia, hypothyroidism, and celiac disease. Additionally, she had smoked for five years but quit 15 years ago, and she had no history of alcohol consumption or drug abuse.

The researchers stated that the pathophysiology of COVID-19 vaccine-induced Takotsubo cardiomyopathy is not yet clear, but that  “several theories have been proposed.” The immune response triggered by COVID-19 vaccines may, for some individuals, “result in an exaggerated inflammatory cascade, leading to endothelial dysfunction, microvascular dysfunction, and myocardial injury.” Vaccination may also stimulate the release of pro-inflammatory factors such as interleukin-6. Additionally, the stress response induced by COVID-19 vaccination could potentially “dysregulate the autonomic nervous system, contributing to the development of cardiac dysfunction.”

Takotsubo Cardiomyopathy Poses a Life-Threatening Risk

The association between COVID-19 vaccines and Takotsubo cardiomyopathy is not widely known, with only a few reported cases. On Dec. 11, a peer-reviewed study published in the journal Cureus consolidated and analyzed the evidence concerning COVID-19 vaccine-induced Takotsubo cardiomyopathy.

The researchers conducted a literature search and included 15 case reports involving a total of 16 patients. Among them, 14 individuals received mRNA vaccines (Pfizer, Moderna), while two received viral vector vaccines (AstraZeneca). Seven patients developed Takotsubo cardiomyopathy after the first dose and seven after the second dose.

All patients exhibited elevated cardiac troponin levels, abnormal electrocardiogram findings, and reduced left ventricular ejection fraction on echocardiograms. The most predominant symptom among patients was chest pain, followed by dyspnea and nausea. Eventually, 14 patients recovered and were discharged, while two of the patients died.

The researchers noted that 87.5 percent of patients recovered and were discharged, indicating that Takotsubo cardiomyopathy occurring after vaccination is mostly “transient and reversible.” However, the death of 2 of the patients highlights the “potentially life-threatening nature of this vaccine-related adverse event.”

The paper’s authors urge clinicians to consider the possibility of Takotsubo cardiomyopathy, especially among recipients of mRNA vaccines when presented with patients experiencing chest pain or dyspnea symptoms after vaccination.

The study also mentioned that vaccines developed for COVID-19 have various side effects, including pain and swelling at the injection site, fever, headache, myalgia (muscle pain), fatigue, and nausea.

Reposted from: https://www.theepochtimes.com/health/research-covid-19-vaccines-may-trigger-takotsubo-cardiomyopathy-5552303

Editor's Note: 

Over 3,000 peer-reviewed articles have been published on COVID vaccine injuries. Find links to these studies at COVID Vaccine Injuries, REACT19, Substack and OpenVAERS . 


Myocarditis and COVID-19 Vaccines: Special Report by The Epoch Times (September 2023)

Comments

Post a Comment

Popular posts from this blog

Dr Peter McCullough: How to Detox Spike Protein from Body

By Dr Frank Yap, M.D. -
Image
Base Spike Detox According to Dr Peter McCullough (in a Twitter post): Base Spike Detox is what I am currently using in my practice for those who have had COVID-19 multiple times, one or more of the COVID-19 vaccines, or both and believe persistent SARS-CoV-2 Spike protein could be causing problems in their body.  I have arrived, based on the emerging scientific literature (1) and my clinical observation, that three OTC products are essential as a triple base combination: Nattokinase 2000 FU (100 mg) twice a day Bromelain 500 mg once a day Nano/Liposomal Curcumin 500 mg twice a day Related: Nattokinase, Bromelain and Curcumin from The Wellness Company Additional products can be added, including NAC, IVM (Ivermectin), HCQ (Hydroxychloroquine), fluvoxamine, low-dose naltrexone, and blood thinners, depending on the clinical evaluation and the syndrome. The therapeutic objectiv
Read more

Dr Peter McCullough: Povidone Iodine, Oral and Nasal Hygiene (2024)

By Dr Frank Yap, M.D. -
Image
Dr. Peter McCullough is an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas, USA. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough Protocol 2022 Updates:  Double blind randomized controlled trial of saline solution gargling and nasal rinsing in COVID infection (Nov 2023) What really killed COVID-19 patients: It wasn't a cytokine storm, suggests study  (2023) Everyone is familiar with nasal and oral swab testing for COVID-19. It should be obvious the virus is replicating in the nose, and with Omicron, the speed of replication has become much greater than the pri
Read more

Dr Peter McCullough Early Treatment Protocol

By Dr Frank Yap, M.D. -
Image
Well-respected North Texas cardiologist, Dr. Peter McCullough has impeccable academic credentials. He's an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough et al. Reviews in Cardiovascular Medicine, 2020 McCullough Protocol 2022 Updates:  How to Detox Spike Protein from Body  (November 2023) Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2 (October 2024) Paxlovid for Vaccinated or Unvaccinated Adult Outpatients with C
Read more

Find a Doctor to prescribe Hydroxychloroquine, Ivermectin and Early Outpatient Treatments (2024)

By Dr Frank Yap, M.D. -
Image
Treatment should start based on clinical suspicion as soon as possible, preferably within the first 3 days of symptoms. Perform PCR testing, but do not withhold treatment pending results. 'Early' treatment will make significant difference in outcome as opposed to late treatment.  Related: How can I get Ivermectin? See the directory of professionals in US below. Directory of Doctors (by State) Prescribing Effective Outpatient COVID-19 Therapy USA ​ MULTIPLE STATES (Telemedicine or online consultation) The Wellness Company ( twc.health ) Medical Specialty: Family Medicine, Functional Medicine Supported Protocols: I-PREVENT (COVID Protection), I-CARE (Early at-home treatment), I-RECOVER (Long COVID and Post-Vaccine treatment) Dr. Miguel Antonatos (IVM) (855) 767-8559  https://text2md.com (States: AL, AZ, CO, FL, GA, IA, ID, IL, KS, KY, MD, ME, MI, MN, MS, ND, NE, NJ, NV, OK, SC, SD, TN, UT, VT, WA, WI, WV)
Read more

How to Make Povidone Iodine 1% Nasal Spray (2024)

By Dr Frank Yap, M.D. -
Image
Is povidone iodine the next ivermectin or hydroxychloroquine? Is there any evidence that povidone iodine can treat COVID-19? Iodine 1% Nasal Spray is part of the FLCCC I-CARE early treatment protocol :  Nasal spray with 1% povidone-iodine: 2-3 times a day. Do not use for more than 5 days in pregnancy. If 1% product is not available, dilute the more widely available 10% solution and apply 4-5 drops to each nostril every 4 hours. Use 1 % povidone iodine commercial product as per instructions 2–3 x daily. If 1 %-product not available, must first dilute the more widely available 10 %-solution. To make 1% povidone iodine concentrated solution from 10% povidone iodine solution, one dilution method is as follows: – First pour 1½ tablespoons (25ml) of 10% povidone/ iodine solution into a nasal irrigation bottle of
Read more

FLCCC I-Recover Protocol: Post Vaccine Treatment Protocol (2024)

By Dr Frank Yap, M.D. -
Image
Over the last three years, the COVID-19 pandemic has transformed almost every aspect of our lives before we've had time to stop and question it. Although no official definition exists for post-COVID-vaccine syndrome, a temporal correlation between a patient receiving a COVID-19 vaccine and beginning or worsening of clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury, when the symptoms are unexplained by other concurrent causes. Dr. Paul Marik and Dr. Pierre Kory are pleased to introduce the I-RECOVER: Post-Vaccine Treatment protocol, designed to help people who have experienced adverse symptoms after a COVID vaccine. Kory and Marik are both part of the FLCCC, which was founded in 2020 to share early treatment protocols for COVID-19. Kory is an ICU specialist, triple board certified in internal medicine, critical care and pulmonary medicine. He now runs a private tele-health practice specializing in the treatment
Read more

Front Line Doctors Ivermectin Protocol for Prevention and Treatment of COVID-19 (2024)

By Dr Frank Yap, M.D. -
Image
The Front Line COVID-19 Critical Care (FLCCC) Alliance was initially formed as a working group during the early COVID-19 pandemic days in response to multiple early reports of COVID patients with an inexplicably high need for prolonged mechanical ventilation and an excessive death rate.  Based on rapidly emerging clinical trials evidence, the FLCCC team has developed the   I-MASK+ protocol   ( is now divided into I-Prevent and I-Care protocols ) for prophylaxis and at home treatment of early stage COVID-19. Quercetin, zinc and a number of nutrients and drugs are part of this protocol, not only for critical care but also for prophylaxis and mild disease being treated at home. This article, we will dive deeper to provide the scientific background, related references and rationale of the FLCCC protocols. FLCCC ( Front Line COVID-19 Critical Care)  Protocols I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19 was designed for use as a prevention and in early outpatien
Read more

Quercetin and Zinc: Zelenko Treatment Protocol

By Dr Frank Yap, M.D. -
Image
As of July 2024, more than 35 studies on the topic of zinc and COVID-19  ( c19zinc.com )  (constantly updated) and more than 10 studies on quercetin and COVID-19 have been published  ( c19quercetin.com ).  Dr. Zelenko’s main hypothesis based on the data showing that early intervention and treatment of high-risk patients with COVID-19 results in significantly few hospitalizations and deaths. This treatment regimen involving zinc, low-dose hydroxychloroquine, and azithromycin (published in the International Journal of Antimicrobial Agents ) is also apparently known as, “The Zelenko Protocol.” Quercetin and Zinc The Zelenko Covid-19 Protocols was developed by Dr Vladimir Zelenko. The protocol has as its centerpiece, but not exclusive piece, the combined use of  Hydroxychloroquine  (HCQ) and Zinc as a means by which a person can both help to prevent or mitigate the contraction of COVID-19, or can actually treat the disease once it has been diagnosed.  Quercetin is a natural antihistamine a
Read more

FLCCC I-CARE COVID Treatment Protocol for Outpatients (2024)

By Dr Frank Yap, M.D. -
Image
Early treatment is critical and the most important factor in managing this disease. COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is not required. Treatment should be initiated immediately after the onset of flu-like symptoms. The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. About I-CARE Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Please be sure you are using the latest version of this protocol. Warning (anesthesia and surgery): Please notify your anesthesia team if you are using the followi
Read more

America's Frontline Doctors Early Treatment Protocol and Contact a Physician

By Dr Frank Yap, M.D. -
Image
  SELF-HELP without a Doctor ( source ) Zinc  50 mg daily (can take half twice daily if upset stomach) Quercetin  500 mg twice a day three times a day if sick (switch to HCQ/IVM if available) Vitamin D3  40,000-50,000 for five days Melatonin  5 mg - 20 mg nightly for 14 days stomach) Pepcid  40-80 daily 14 days – women or Cimetidine 400 daily -men Full Aspirin  (325 mg) daily one month N acetyl cysteine (NAC)  Up to 2000-2400 mg 1-2 days, then 1000-1200 mg for a week Treatment: Latest Prescriptions ( source ) Monoclonal Antibodies:  outpatient, FDA approved, early treatment, within 10 days Only. Note and Update: Omicron variant XBB found to be resistant to monoclonal antibody treatments ( New England Journal of Medicine . Dec 2022) HCQ  200 mg twice a day 7 days or IVM (weight based 0.4/kg) 20-36 mg daily 2-5 days Fenofibrate (Tricor – anti-lipid)  145 mg daily (inflammatory/cytokine phase. Antioxidant) Cyproheptadine (Periactin – antihistamine)  4 mg BID for 14 days (cytokine phase) D
Read more

Labels

Show more

Archive

Show more